Letters to the Editor

Simultaneous Percutaneous Closure of Patent Foramen Ovale and Left Atrial Appendage

Cierre percutáneo simultáneo de foramen oval permeable y orejuela izquierda

To the Editor,

We report the case of a 59-year-old male smoker with hypertension and dyslipidemia who, in 2007, was diagnosed with atrial fibrillation and patent foramen ovale (PFO) after suffering a cerebral ischemic attack in the region of the middle cerebral artery. The high risk of a further cerebral ischemic attack (score of 3 on the CHADS 2) was an indication for long-term oral anticoagulation. However, as it was difficult to achieve adequate levels of anticoagulation and to avoid further anticoagulation therapy, percutaneous closure of the left atrial appendage (LAA) using an Amplatzer cardiac plug (ACP) and of the PFO using an Amplatzer septal occluder (ASO) was proposed. The patient agreed to this approach.

Two- and 3-dimensional transesophageal echocardiography (2D and 3D TEE) showed the LAA anatomy to be favorable to closure and indicated the presence of PFO at the level of the fossa ovalis.

Following usual practice in the catheterization laboratory, LAA closure was carried out under fluoroscopic guidance; 2D and 3D TEE were also used. These techniques were used to control passage into the left atrium through the PFO and to measure the longitudinal diameters of the base and the middle third (20, 18 and 16 mm, respectively, in left and right anterior oblique projection using fluoroscopy, and 22 mm, 18 mm and 17 mm using 2D TEE at orientations of 0° and 116°). A 20-mm ACP device mounted on the corresponding delivery system was used for closure. The device was released after verifying that it was correctly positioned using angiography and 2D and 3D TEE. Control angiography was then used to check the device's stability and to determine that there was no contrast flow to the LAA; TEE was used to check that there was minimal flow penetration into the LAA at the edges of the device (Fig. 1).

Using the same delivery system, a 25-mm cribriform ASO device was implanted and its stability and efficacy confirmed in the same way. Again, no passage of contrast or color on

Figure 1. A: image obtained using 2-dimensional transesophageal echocardiography and showing minimum residual flow (arrows) between the edges of the device and the cavity of the appendage (asterisk). B: 2-dimensional transesophageal echocardiography image shows Amplatzer plug (arrow) released and occluding the entrance to the left atrial appendage (asterisk). C: fluoroscopic image showing the Amplatzer septal occluder device implanted at the level of foramen ovale (red arrow) and the Amplatzer cardiac plug device implanted in the left atrial appendage (yellow arrow). Blue arrow: transesophageal echocardiography probe.

Figure 2. A: image obtained using 3-dimensional transesophageal echocardiography and showing the position of the device used to close the patent foramen ovale in the atrial septum, and the Amplatzer cardiac plug occluding the left atrial appendage. B: 3-dimensional transesophageal echocardiography image of the device (Amplatzer septal occluder) used to close the patent foramen ovale in the atrial septum. ASO, Amplatzer septal occluder; IAS, interatrial septum; LAA, left atrial appendage; MV, mitral valve.
the Doppler image was observed for the PFO closure device (Fig. 2).

The patient was discharged without complications the following day on dual antiplatelet therapy (aspirin and clopidogrel).

Percutaneous closure of the LAA is offered as a new treatment option for patients at risk of embolism in whom it may be difficult to achieve satisfactory anticoagulation control or where anticoagulation treatment is not possible or desirable.1 Ninety percent of thrombi in patients with nonrheumatic atrial fibrillation occur in the LAA.2 A PFO closure is also possible and is recommended in situations where there is a risk of paradoxical embolism,3 regardless of recent discussions and reports on its long-term usefulness.

This case shows that it is possible to carry out the double percutaneous procedure in the same intervention and to thereby act directly on the embolic focus of the LAA while also closing the PFO.

Manuel Paulo, a Eulogio García, a Rosa Ana Hernández-Antolín, a and Carlos Almería a, b

Endovascular Diagnosis and Palliative Treatment of a Pulmonary Artery Angiosarcoma

Diagnóstico y tratamiento paliativo endovascular de un angiosarcoma de arteria pulmonar

To the Editor,

A 62-year-old woman with dyspnea at rest and chest pain persisting for 2 months was referred to our hospital with a presumptive diagnosis of pulmonary thromboembolism (PTE). On admission the physical examination revealed signs of right-sided heart failure and systolic murmur in the pulmonary area. The electrocardiogram showed signs of overload of the right chambers, whereas transesophageal echocardiography showed dilatation of the pulmonary trunk, a heterogeneous hypoechoic image straddling the bifurcation, and a right ventricle with severe dilatation and deterioration of the systolic function. A ventilation-perfusion scintigraphy suggested a high probability of PTE and, therefore, anticoagulant therapy with sodium heparin was initiated. Venous Doppler ultrasound of the lower limbs ruled out the presence of thrombosis. The differential diagnosis included a tumor of the pulmonary artery.

Computed tomography angiography of the chest showed an occlusive endoluminal filling defect that involved the pulmonary trunk, extending toward both main branches but primarily affecting the left: some sectors of the image were late-phase contrast-enhanced (Fig. 1A). The lesion was confirmed by pulmonary angiography (Fig. 1B), and found to produce a critical obstruction with a translesional pressure gradient of 53 mmHg. Atypical, vimentin-positive Ki67 cells were observed in specimens taken with a biopome. The anatomical pathology diagnosis was angiosarcoma of the pulmonary trunk.

Given the infiltration of the pulmonary artery and adjacent cardiac structures and the patient’s poor overall condition and high surgical risk, it was considered that the tumor could not be surgically resected. To relieve the dyspnea, palliative treatment consisting of angioplasty of the pulmonary trunk with 2 stents of 26/40 mm and 24/60 mm was successfully undertaken (Fig. 2).

Following the procedure, the patient’s symptoms improved. She was discharged with functional class II dyspnea and was able to return to her normal activities. After 4 months, she presented progressive dyspnea up to functional class III, caused by severe


doi:10.1016/j.rec.2010.12.014

Figure 1. A: tomography angiography of the chest; endoluminal mass affecting the trunk (white arrow) and invading the right branch of the pulmonary artery (yellow arrow); its relationship with the aorta can also be seen (blue arrow). B: pulmonary angiography confirming the previous finding: absence of filling with iodinated contrast material.